Abraxis Bioscience Launches Abraxane In China

Abraxis Bioscience has launched Abraxane for Injectable Suspension in China, for the treatment of patients with metastatic breast cancer. In a global phase-III clinical trial, and in phase-II clinical trial in China, the tumor response rate in patients was nearly double the response rate, compared to patients who received solvent-based paclitaxel.

Abraxane is approved by the State Food and Drug Administration for the treatment of breast cancer, after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

The recommended regimen is 260mg/m2 administered intravenously over 30 minutes every three weeks.

Abraxane uses nab-Technology to deliver the drug paclitaxel to the tumor site. The formulation combines paclitaxel with albumin, a naturally occurring protein, which eliminates the need for solvents in the standard delivery of chemotherapy.

Prof. Zefei JIANG, Director of Breast Cancer Department, said: “The availability of new therapies, like Abraxane, is important to meeting the unmet needs of women fighting breast cancer in China.”